| For: | Kram M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 2023; 15(2): 201-207 [PMID: 36926236 DOI: 10.4254/wjh.v15.i2.201] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v15/i2/201.htm |
| Number | Citing Articles |
| 1 |
Shima Mimura, Asahiro Morishita, Kyoko Oura, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara. Galectins and Liver Diseases. International Journal of Molecular Sciences 2025; 26(2) doi: 10.3390/ijms26020790
|
| 2 |
Anna Lisa Cammarota, Antonia Falco, Anna Basile, Carlo Molino, Massimiliano Chetta, Gianni D’Angelo, Liberato Marzullo, Margot De Marco, Maria Caterina Turco, Alessandra Rosati. Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment. Cancers 2023; 15(19) doi: 10.3390/cancers15194825
|
| 3 |
Anjali Gangwar, Sapna Saini, Rashmi Sharma. Galectins as Drivers of Host–Pathogen Dynamics in Mycobacterium tuberculosis Infection. ACS Infectious Diseases 2025; 11(6) doi: 10.1021/acsinfecdis.4c01056
|
| 4 |
Alam Zeb. Pharmacological Targets in Metabolic Diseases. 2026; doi: 10.1016/B978-0-443-27370-4.00023-8
|
| 5 |
Agata Morawska, Rafał Frankowski, Mikołaj Grabarczyk, Marcin Kosmalski, Monika Różycka-Kosmalska. Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications. Life 2025; 15(11) doi: 10.3390/life15111713
|
| 6 |
Yasmin Mohtasham Kia, Alessandro Cannavo, Pegah Bahiraie, Sanam Alilou, Behrad Saeedian, Nastaran Babajani, Elina Ghondaghsaz, Amirmohammad Khalaji, Amir Hossein Behnoush, Sowjanya Thatikonda. Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation. Disease Markers 2023; 2023 doi: 10.1155/2023/2097012
|
| 7 |
Dong Jiang, Lin Tong, Jiao Yu, Guo-Feng Gao. Predictive value of core-fucosylated low-molecular-weight kininogen levels in patients with liver fibrosis: A prospective study. World Journal of Gastroenterology 2025; 31(29): 105210 doi: 10.3748/wjg.v31.i29.105210
|
| 8 |
John Nzobokela, Lweendo Muchaili, Alick Mwambungu, Sepiso K. Masenga, Annet Kirabo. Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome. Frontiers in Cardiovascular Medicine 2025; 12 doi: 10.3389/fcvm.2025.1661563
|
| 9 |
Dileep G. Nair, Ralf Weiskirchen. Liver Fibrosis: Current Treatments, Bottlenecks, and Future Prospects for Translational Medicine. Sci 2026; 8(1) doi: 10.3390/sci8010009
|
| 10 |
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacological Reviews 2024; 76(3) doi: 10.1124/pharmrev.123.001087
|
| 11 |
Alka Singh, Ansab Akhtar, Prashant Shukla. Exploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives. ADMET and DMPK 2025; 13(4) doi: 10.5599/admet.2874
|
| 12 |
David S. Kim, Tetsuo Horimatsu, Mourad Ogbi, Brandee Goo, Hong Shi, Praneet Veerapaneni, Ronnie Chouhaita, Nicole Cyriac, Mary Moses, Rosaria Prasad, Stephen Cave, Tyler W. Benson, Ragheb Harb, Ghaith Aboud, Hunter G. Sellers, Mitchell Shivers, Stephen Haigh, David J. Fulton, Gábor Csányi, Yuqing Huo, Xiaochun Long, Philip Coffey, Richard Lee, Avirup Guha, Wenbo Zhi, Lufei Young, Darryl C. Zeldin, Sung Hee Hwang, Bruce D. Hammock, Neal L. Weintraub, Ha Won Kim. Soluble epoxide hydrolase in the liver orchestrates abdominal aortic aneurysm formation in mice. Communications Biology 2026; 9(1) doi: 10.1038/s42003-026-09765-x
|
| 13 |
Alyanna M. Popatia, Ahmad Sharanek, Arezu Jahani-Asl. Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation. Signal Transduction and Targeted Therapy 2026; 11(1) doi: 10.1038/s41392-026-02768-4
|
| 14 |
Tian Lan, Wen Wang, Xi-xi Zeng, Wei-li Mao, Tao Lu, Si-wei Wang. Limonin mitigates hepatic senescence and fibrosis in MASH mice by targeting STAT3 to inhibit Galectin-3/mTORC1 signaling. Phytomedicine 2026; 156 doi: 10.1016/j.phymed.2026.158244
|
| 15 |
Mohammadjavad Sotoudeheian. Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease. Protein & Peptide Letters 2024; 31(4) doi: 10.2174/0109298665301698240404061300
|
| 16 |
Veronika A. Prikhodko, Sergey V. Okovityi. Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities. Biomedicines 2026; 14(4) doi: 10.3390/biomedicines14040909
|
| 17 |
Huseyin Ali Ozturk, Hilmi Erdem Sumbul. Liver stiffness and serum galectin 3 level significantly increases in patients with prediabetes: a fibroscan study. PeerJ 2025; 13 doi: 10.7717/peerj.19377
|
| 18 |
Ming-Shyan Lin, Ya-Chi Tu, Yu-Sheng Lin, Meng-Hung Lin, Chun-Liang Lin, Ming-Horng Tsai, Yung-Yu Hsieh, Tien-Hsing Chen, Mei-Yen Chen, Chung-Sheng Shi. Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study. Therapeutic Advances in Chronic Disease 2024; 15 doi: 10.1177/20406223241302719
|
| 19 |
Shunsuke Miyauchi, Miki Kawada-Matsuo, Hisako Furusho, Hiromi Nishi, Ayako Nakajima, Pham Trong Phat, Fumie Shiba, Masae Kitagawa, Kazuhisa Ouhara, Noboru Oda, Takehito Tokuyama, Yousaku Okubo, Sho Okamura, Taiichi Takasaki, Shinya Takahashi, Toru Hiyama, Hiroyuki Kawaguchi, Hitoshi Komatsuzawa, Mutsumi Miyauchi, Yukiko Nakano.
Atrial Translocation of
Porphyromonas gingivalis
Exacerbates Atrial Fibrosis and Atrial Fibrillation
. Circulation 2025; 151(21) doi: 10.1161/CIRCULATIONAHA.124.071310
|
| 20 |
Vesna Brzački, Andriana Jovanović, Andrija Rančić, Snežana Tešić-Rajković, Gordana Petrović, Ivan Nagorni, Marko Stojanović, Elena Stanković, Stefan Momčilović. Circulating and Tissue Galectin-3 in Gastrointestinal Inflammation: Clinical Significance and Biomarker Potential. Cells 2025; 14(19) doi: 10.3390/cells14191521
|
| 21 |
Jerzy Ostrowski, Piotr Socha, Joanna Ziemska-Legięcka, Izabela Kubiszewska, Anna Świąder-Leśniak, Irena Jankowska, Wojciech Jańczyk, Aldona Wierzbicka-Rucińska, Krzysztof Goryca, Michalina Dabrowska, Jacek Michalkiewicz, Natalia Zeber-Lubecka. Transcriptome profiles of peripheral blood mononuclear cells differentiate male adolescents with non-alcoholic fatty liver disease from healthy peers. World Journal of Hepatology 2025; 17(12): 113359 doi: 10.4254/wjh.v17.i12.113359
Abstract(62) |
Core Tip(58) |
Full Article(HTML)(224)
|
Full Article (PDF)-3261K(48)
|
Full Article with Cover (PDF)-3514K(29)
|
Full Article (XML)-155K(38)
|
Audio-513K(3)
|
Peer-Review Report-246K(22)
|
Answering Reviewers-84K(41)
|
Supplementary Material-534K(26)
|
Times Cited (1)
|
Total Visits (430)
|
Open
|
| 22 |
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, Antonios Chatzigeorgiou. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease. Hormones 2024; 23(4) doi: 10.1007/s42000-024-00588-1
|
| 23 |
Nevena M Gajovic, Ivan P Jovanovic, Miodrag V Jocic, Bojan Stojanovic, Irfan F Corovic, Nevena Todorovic, Bojana J Simovic Markovic, Amedeo Amedei. Exploring the impact of galectins on liver cancer: From immunopathogenesis to potential targets. World Journal of Gastroenterology 2025; 31(25): 107260 doi: 10.3748/wjg.v31.i25.107260
|
| 24 |
Shifang Tang, Jürgen Borlak. Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures. Hepatology 2024; 80(4) doi: 10.1097/HEP.0000000000000780
|
| 25 |
Adrian Martuszewski, Patrycja Paluszkiewicz, Rafał Poręba, Paweł Gać. Galectin-3 in Cardiovascular Health: A Narrative Review Based on Life’s Essential 8 and Life’s Simple 7 Frameworks. Current Issues in Molecular Biology 2025; 47(5) doi: 10.3390/cimb47050332
|
| 26 |
Praveenkumar Shetty, Pavan K. Jayaswamy, Prakash Patil, M. Vijaykrishnaraj, Jamboor K. Vishwanatha, Sukanya Shetty. Cardiometabolic Diseases. 2025; doi: 10.1016/B978-0-323-95469-3.00029-2
|
| 27 |
Qian Jiang, Qijin Zhao, Pingping Li. Galectin-3 in metabolic disorders: mechanisms and therapeutic potential. Trends in Molecular Medicine 2025; 31(5) doi: 10.1016/j.molmed.2024.11.006
|
| 28 |
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo. Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis. International Journal of Molecular Sciences 2025; 26(4) doi: 10.3390/ijms26041778
|
| 29 |
Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Jorge L. Poo, Nahum Méndez-Sánchez. Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence. Archives of Medical Research 2026; 57(4) doi: 10.1016/j.arcmed.2026.103387
|
| 30 |
Paolo Comeglio, Giulia Guarnieri, Sandra Filippi, Ilaria Cellai, Gabriele Acciai, Ian Holyer, Fredrik Zetterberg, Hakon Leffler, Barbro Kahl-Knutson, Erica Sarchielli, Annamaria Morelli, Mario Maggi, Robert J. Slack, Linda Vignozzi. The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1430109
|
| 31 |
Ikki Sakuma, Rafael C. Gaspar, Ali R. Nasiri, Sylvie Dufour, Mario Kahn, Jie Zheng, Traci E. LaMoia, Mateus T. Guerra, Yuki Taki, Yusuke Kawashima, Dean Yimlamai, Mark Perelis, Daniel F. Vatner, Kitt Falk Petersen, Maximilian Huttasch, Birgit Knebel, Sabine Kahl, Michael Roden, Varman T. Samuel, Tomoaki Tanaka, Gerald I. Shulman. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings of the National Academy of Sciences 2025; 122(18) doi: 10.1073/pnas.2502978122
|
| 32 |
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese. Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon. Current Hepatology Reports 2024; 23(1) doi: 10.1007/s11901-023-00629-0
|
| 33 |
Eda Ates, Hien Thi My Ong, Seung-Min Yu, Ji-Hoon Kim, Min-Jung Kang. Comparative Analysis of the Total Proteome in Nonalcoholic Steatohepatitis: Identification of Potential Biomarkers. Molecular & Cellular Proteomics 2025; 24(3) doi: 10.1016/j.mcpro.2025.100921
|
| 34 |
Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu. Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD. ImmunoTargets and Therapy 2025; doi: 10.2147/ITT.S530451
|